Welcome

The Vermont Center on Behavior and Health (VCBH), led by Director Stephen T. Higgins, PhD, is an interdisciplinary research center committed to investigating relationships between personal behavior patterns (i.e., lifestyle) and risk for chronic disease and premature death. Our work has historically focused on health disparities for the most vulnerable populations, particularly among the socioeconomically disadvantaged where these risk factors are overrepresented.

 

VCBH logo

Located in Burlington, VT at the University of Vermont, Larner College of Medicine, VCBH researchers have a specific focus on understanding mechanisms underpinning risk and developing effective interventions and policies to promote healthy behavior. A common thread across VCBH research projects is the application of knowledge from the disciplines of behavioral economics and behavioral pharmacology to increase understanding of vulnerability to unhealthy behavior and the use of incentives and other behavioral and pharmacological interventions to support healthy behavior change interventions and policies.

Stay Connected with VCBH

Join our mailing list to get the latest
on news and events.

Follow us on our social media channels

Twitter icon circle Facebook icon circle LinkedIn icon YouTube Icon

Upcoming VCBH Events

Monthly Lecture Series:

November 20:
Joseph McClernon, PhD
Duke University

December 18:
Hugh Garavan, PhD
University of Vermont

Visit the Center on Rural Addiction

CORA_transparents

 


VCBH Career Opportunities

Postdoctoral Research Fellowships
Click here for more information.

VCBH News

Study Finds Lowering Nicotine Reduces Smoking Addictiveness in Vulnerable Populations

October 20, 2020 by Nicole Twohig

A JAMA Network Open study, led by Stephen T. Higgins, Ph.D., director of the Vermont Center on Behavior and Health at the University of Vermont’s Larner College of Medicine, provides evidence that, even in smokers from vulnerable populations, reducing nicotine content to low levels decreases addictiveness – a timely finding as the Food and Drug Administration (FDA) considers a policy to lower nicotine content in all cigarettes sold in the U.S.

A sample package of unlabeled study cigarettes used by researchers at the University of Vermont, Brown University and Johns Hopkins University. (Photo: Vermont Center on Behavior and Health)

More than 480,000 U.S. deaths per year, as well as diseases affecting 16 million living Americans, can be attributed to cigarette smoking, according to the Centers for Disease Control and Prevention. In particular, this behavior continues to be overrepresented among those with mental illness, substance use disorders, and socioeconomic disadvantage.

An October 20 study in JAMA Network Open provides evidence that, even in smokers from vulnerable populations, reducing nicotine content to low levels decreases addictiveness – a timely finding as the Food and Drug Administration (FDA) considers a policy to lower nicotine content in all cigarettes sold in the U.S.

Led by Stephen T. Higgins, Ph.D., director of the Vermont Center on Behavior and Health at the University of Vermont’s (UVM) Larner College of Medicine, in collaboration with colleagues at Brown University and Johns Hopkins University, the study sought to determine if reducing the nicotine content of cigarettes decreases smoking rates and nicotine dependence severity among adults with psychiatric disorders or socioeconomic disadvantage.

Three double-blind, randomized clinical trials were conducted at UVM, Brown, and Johns Hopkins between October 2016 and September 2019, with data analyzed from September 2019 to July 2020. A total of 775 daily smokers with affective disorders, opioid use disorder, or socioeconomic disadvantage who were NOT currently trying to quit smoking were deemed eligible.

Participants were randomly assigned to use research cigarettes for 12 weeks that contained either 0.4 mg nicotine/g tobacco, 2.4 mg nicotine/g tobacco (both known as very low-nicotine content cigarettes or VLNCs), or 15.8 mg nicotine/g tobacco (a level comparable to a standard commercial cigarette). NIH provided the study cigarettes, and all were identical in appearance. Assignment to the two VLNCs decreased daily smoking rate by an average of roughly 30 percent, as well as nicotine dependence severity and biochemical measures of smoke exposure compared to those using the cigarettes with nicotine content at levels in commercial cigarettes.

“We know that lower smoking rate and dependence severity are two important predictors of successful smoking cessation should someone attempt to quit,” said Higgins, who is presenting these latest findings to a conference of tobacco researchers and NIH-FDA officials on October 20, 2020. “Our findings in this and earlier studies suggest that lowering the nicotine content in all cigarettes to minimally addictive levels would benefit all smokers, including those most vulnerable to smoking and addiction.”